LivAyur

Bengaluru, India Founded: 2019 • Age: 7 yrs Listed
Offers Ayurvedic remedies, health tips, consultations, and wellness products online.
Request Access
Report Incorrect Data
Page last updated

About LivAyur

LivAyur is a publicly listed company based in Bengaluru (India) founded in 2019. It offers Ayurvedic remedies, health tips, consultations, and wellness products online. It operates on a B2C and D2C model. The company has 3,328 employees. Its Indian entity Emami Limited reported revenue of ₹3,865 Cr. LivAyur offers products and services including Medha Vati, Panchakarma, and Ashwagandha. Its focus areas include Health, Alternative Medicine, Ayurveda and Wellness Products.

Company details

Livayur, under Emami Ltd, is a platform that shares ancient Ayurvedic knowledge with modern applications. It covers topics like healthy body management, nutritious food advice, natural healing remedies, and mental health support. Based in Kolkata, India, it provides e-books, live sessions, diagnostic tools, and products for conditions such as diabetes and immunity. The site serves individuals seeking holistic health solutions through educational content and direct purchases.

  • Headquarters Bengaluru, India
  • Employees 3,328
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website livayur.com
  • Social Facebook Instagram YouTube
  • Legal Name Emami Ltd
  • Date of Incorporation 11 Mar, 1983
  • Jurisdiction Kolkata, West Bengal, India
Operational Areas
Healthcare → Alternative Medicine Products
Key Metrics
  • Market Cap
    ₹16,190 Cr

    EMAMILTD · NSE

  • Share Price
    ₹359.75

    -3.01% today

  • Revenue
    ₹3,780 Cr

    FY 2025-26 · -0.8% YoY

  • EBITDA
    ₹949 Cr

    Margin 25.1%

  • Net Profit
    ₹735 Cr

    FY 2025-26 · -3.3% YoY

  • P/E (TTM)
    21.5x

    P/B 5.6x

  • ROE
    27.6%

    ROCE 28.8%

  • Debt / Equity
    0.04

    Interest cover 1.4x

  • Employee Count
    3,328

Products & Services of LivAyur

LivAyur offers a comprehensive portfolio of products and services, including Medha Vati, Panchakarma, and Ashwagandha.

Medha Vati
Ayurvedic Medicine

Herbal supplement for cognitive and mental health support

Panchakarma
Therapy Service

Ayurvedic detoxification process for overall health maintenance

Ashwagandha
Herbal Product

Natural herb used for stress relief and immunity boosting

Apps and channels of LivAyur

its YouTube channel LivAyur India has 541 subscribers and 30 videos.

LivAyur India
YouTube 541 subscribers 30 videos Howto & Style
Open channel

Videos from LivAyur

The most watched videos on LivAyur's YouTube channel, LivAyur India (541 subscribers). Click a video to play it here.

Home-Made Remedies For Cold And Sinus
9.4K views
Medha Vati: Ayurvedic Formula for Mental Well-Being!
6.5K views
Prostatomegaly Management: Ayurvedic Herbs, Yoga Asanas & More
6.2K views
White Pumpkin: Know Its Benefits
6.1K views

More on LivAyur India.

Board of directors of Emami Limited (LivAyur)

Emami Limited is the primary company behind LivAyur. The board of Emami Limited currently have 18 directors; the longest-serving is Radhe Shyam Goenka, appointed in 1994. 17 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Radhe Shyam Goenka
DIN 00152880
Director03 May 199432 yrs 5 moEmami Limited
Radhe Shyam Agarwal
DIN 00152996
Director03 May 199432 yrs 5 moEmami Limited
Sushil Kumar Goenka
DIN 00149916
Whole-time director17 May 199531 yrs 5 moEmami Limited
Mohan Goenka
DIN 00150034
Whole-time director15 Jan 200521 yrs 9 moEmami Limited
Harsha Vardhan Agarwal
DIN 00150089
Managing Director15 Jan 200521 yrs 9 moEmami Limited
Aditya Vardhan Agarwal
DIN 00149717
Director01 Jul 200719 yrs 4 moEmami Limited
Priti A Sureka
DIN 00319256
Whole-time director30 Jan 201016 yrs 9 moEmami Limited
Prashant Goenka
DIN 00703389
Whole-time director20 Jan 201412 yrs 9 moEmami Limited
Naresh Hiralal Bhansali
DIN 00793959
CFO05 May 201412 yrs 5 moEmami Limited
Chandra Kumar Dhanuka
DIN 00005684
Director02 Aug 20179 yrs 3 moEmami Limited
Debabrata Sarkar
DIN 02502618
Director21 Feb 20197 yrs 8 moEmami Limited
Mamta Binani
DIN 00462925
Director29 Oct 20215 yrsEmami Limited
Avani Vishal Davda
DIN 07504739
Director02 Aug 20224 yrs 3 moEmami Limited
Anjani Kumar Agrawal
DIN 08579812
Director02 Aug 20224 yrs 3 moEmami Limited
Anjan Snehmoy Chatterjee
DIN 00200443
Director02 Aug 20224 yrs 3 moEmami Limited
Anand Nandkishore Rathi
DIN 00112853
Director02 Aug 20224 yrs 3 moEmami Limited
Rajiv Khaitan
DIN 00071487
Director02 Aug 20224 yrs 3 moEmami Limited
Ravi Varma
DIN 08054978
Company Secretary01 Aug 20251 yr 3 moEmami Limited

IPO & Listings of LivAyur

LivAyur is a publicly listed company on the NSE with ticker symbol EMAMILTD in India, operating in the FMCG sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: EMAMILTD
  • Listed entityEmami Limited
  • Exchange sectorFMCG

Financials of LivAyur

Exchange-reported figures of Emami Limited, the listed company behind LivAyur (NSE: EMAMILTD).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹3,780 Cr
-0.8% YoY
EBITDA
₹949 Cr
-6.3% YoY
Profit After Tax
₹735 Cr
-3.3% YoY
Net Worth
₹2,924 Cr
+8.5% YoY
Total Assets
₹3,130 Cr
+11.1% YoY
Total Debt
₹162 Cr
+80.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,7803,8093,5783,4063,1922,8812,655
Revenue growth-0.8%+6.5%+5.1%+6.7%+10.8%+8.5%-
EBITDA9491,013940855933879674
EBITDA margin+25.1%+26.6%+26.3%+25.1%+29.2%+30.5%+25.4%
Profit before tax846894791670688569374
Net profit735760711631801433295
Net profit margin+19.5%+20.0%+19.9%+18.5%+25.1%+15.0%+11.1%
EPS (₹)17.7618.4816.5814.5019.0210.236.68
Balance sheet
Total assets3,1302,8182,5892,4542,4061,9122,093
Net worth2,9242,6952,4472,3032,0771,7631,824
Total debt16289.7993.9590.51282101210
Cash & bank410273201185116360119
Net working capital763603577531389434383
Cash flow
Cash from operations801896779749644922531
Cash from investing(174)(345)(210)(122)(234)(224)(231)
Cash from financing(554)(500)(563)(608)(402)(688)(405)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,0399251,1527999049631,049891
Revenue growth (YoY)+15.0%-3.9%+9.8%-10.3%-0.2%---
Other income18.5023.1819.2421.3721.5921.1614.9321.56
EBITDA225186374177212219334246
EBITDA margin+21.6%+20.1%+32.5%+22.1%+23.5%+22.7%+31.8%+27.6%
Depreciation42.7642.2545.3245.2744.5043.5345.6044.65
Interest5.613.152.922.632.432.782.172.33
Profit before tax195164345150187194301220
Tax55.7720.9025.571.8322.5131.5322.379.44
Net profit139143319148164162279211
EPS (₹)3.153.287.323.403.763.726.394.87
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,0483,1242,9222,9072,8672,5822,390
Revenue growth-2.4%+6.9%+0.5%+1.4%+11.0%+8.1%-
EBITDA940937846777897843589
EBITDA margin+30.8%+30.0%+29.0%+26.7%+31.3%+32.7%+24.6%
Profit before tax901934747606689574338
Net profit802814681565808453275
Net profit margin+26.3%+26.1%+23.3%+19.5%+28.2%+17.5%+11.5%
EPS (₹)19.2819.6815.8913.0019.2810.696.38
Balance sheet
Total assets3,2842,9112,4372,3302,3541,8532,012
Net worth3,1562,8672,3832,2642,0861,7591,802
Total debt91.6614.1022.2420.5322446.53158
Cash & bank31718291.1595.8055.6030857.30
Net working capital672505446444333372294
Cash flow
Cash from operations794864740731596878546
Cash from investing(257)(465)(192)(106)(188)(200)(251)
Cash from financing(462)(368)(546)(612)(398)(679)(399)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue780730958604756781879709
Revenue growth (YoY)+3.1%-6.5%+9.0%-14.7%+0.2%---
Other income53.1824.5719.2153.8520.9166.459.8334.48
Total expenses564533583437556590550483
EBITDA215196375168201191328226
EBITDA margin+27.6%+26.9%+39.2%+27.7%+26.5%+24.4%+37.4%+31.9%
Depreciation34.1335.9440.0940.1539.4539.4439.9839.68
Interest0.890.500.490.470.500.590.460.61
Profit before tax234185354181182217298221
Tax51.3818.2423.98(1.49)18.4427.4918.456.43

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 01 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,0399251,1527999049631,049891
Revenue growth (YoY)+15.0%-3.9%+9.8%-10.3%-0.2%---
Other income18.5023.1819.2421.3721.5921.1614.9321.56
EBITDA225186374177212219334246
EBITDA margin+21.6%+20.1%+32.5%+22.1%+23.5%+22.7%+31.8%+27.6%
Depreciation42.7642.2545.3245.2744.5043.5345.6044.65
Interest5.613.152.922.632.432.782.172.33
Profit before tax195164345150187194301220
Tax55.7720.9025.571.8322.5131.5322.379.44
Net profit139143319148164162279211
EPS (₹)3.153.287.323.403.763.726.394.87
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,7803,8093,5783,4063,1922,8812,655
Revenue growth-0.8%+6.5%+5.1%+6.7%+10.8%+8.5%-
Other income85.1168.1146.8068.9395.2570.2757.07
Total expenses2,8302,7962,6382,5502,2592,0021,981
Employee cost479447396368318309300
EBITDA9491,013940855933879674
EBITDA margin+25.1%+26.6%+26.3%+25.1%+29.2%+30.5%+25.4%
Depreciation177178186247335367336
Interest11.139.349.987.395.0713.2721.01
Profit before tax846894791670688569374
Tax70.8091.1266.7042.14(149)11471.27
Net profit735760711631801433295
Net profit margin+19.5%+20.0%+19.9%+18.5%+25.1%+15.0%+11.1%
EPS (₹)17.7618.4816.5814.5019.0210.236.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital43.6543.6543.6544.1244.1244.4545.32
Reserves & surplus2,8802,6512,4032,2592,0321,7181,778
Shareholders' funds (net worth)2,9242,6952,4472,3032,0771,7631,824
Minority interest(1.54)(1.43)11.129.96(2.30)(0.89)(0.86)
Secured loans12261.7865.1669.4211864.04101
Unsecured loans39.8428.0128.7921.0916436.70109
Total debt16289.7993.9590.51282101210
Total liabilities3,1302,8182,5892,4542,4061,9122,093
Assets
Gross block3,8203,7613,7303,6923,5603,0262,992
Net block8869841,1141,2451,3441,1321,459
Capital work in progress1.3714.967.556.333.086.438.05
Investments834676442293303255156
Inventories400308323328358300245
Sundry debtors343451494415321232308
Cash & bank balances410273201185116360119
Loans & advances310277238246239145293
Total current assets1,4631,3101,2571,1731,0331,038965
Total current liabilities700707680642644604582
Net working capital763603577531389434383
Total assets3,1302,8182,5892,4542,4061,9122,093
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10552.9546.7927.5719.8110.84116
Net cash from operating activities801896779749644922531
Net cash from investing activities(174)(345)(210)(122)(234)(224)(231)
Net cash from financing activities(554)(500)(563)(608)(402)(688)(405)
Net change in cash72.1351.676.1719.217.768.97(106)
Closing cash410273201185116360119
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-0.8%+6.5%+5.1%+6.7%+10.8%+8.5%-
EBITDA growth-6.3%+7.8%+9.9%-8.3%+6.1%+30.4%-
PBT growth-5.4%+13.0%+18.1%-2.7%+20.9%+52.3%-7.4%
Net income growth-3.3%+6.9%+12.7%-21.2%+85.0%+46.7%-
Revenue CAGR (3Y)+3.5%+6.1%+7.5%+8.7%+5.8%+4.4%+2.2%
EBITDA CAGR (3Y)+3.5%+2.8%+2.3%+8.3%+9.3%+7.0%-3.9%
Profitability & leverage
Net income margin+20.5%+21.1%+20.2%+18.4%+26.2%+15.8%+11.4%
Return on capital employed+28.8%+33.5%+31.9%+27.9%+32.1%+29.1%+18.2%
Return on net worth+27.6%+31.2%+30.5%+28.7%+43.6%+25.4%+15.5%
Debt / equity0.040.040.040.080.100.090.08
Long-term debt / equity0.010.010.010.000.000.000.00
Interest cover1.441.121.321.220.852.596.22
Efficiency & per share
Fixed asset turnover1.001.020.960.940.970.960.90
Inventory turnover10.6812.0610.999.939.7010.5711.39
Debtors turnover9.518.067.879.2611.5510.6710.13
EPS (₹)17.7618.4816.5814.5019.0210.236.68
Dividend per share (₹)10.0010.008.008.008.008.004.00
Book value per share (₹)66.9961.7456.0552.2047.0739.6540.24
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue780730958604756781879709
Revenue growth (YoY)+3.1%-6.5%+9.0%-14.7%+0.2%---
Other income53.1824.5719.2153.8520.9166.459.8334.48
Total expenses564533583437556590550483
EBITDA215196375168201191328226
EBITDA margin+27.6%+26.9%+39.2%+27.7%+26.5%+24.4%+37.4%+31.9%
Depreciation34.1335.9440.0940.1539.4539.4439.9839.68
Interest0.890.500.490.470.500.590.460.61
Profit before tax234185354181182217298221
Tax51.3818.2423.98(1.49)18.4427.4918.456.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,0483,1242,9222,9072,8672,5822,390
Revenue growth-2.4%+6.9%+0.5%+1.4%+11.0%+8.1%-
Other income11915769.2448.0012310494.09
Total expenses2,1082,1862,0752,1291,9701,7391,801
Employee cost361352319297279267256
EBITDA940937846777897843589
EBITDA margin+30.8%+30.0%+29.0%+26.7%+31.3%+32.7%+24.6%
Depreciation156158167215328361326
Interest1.962.112.123.733.4512.0118.90
Profit before tax901934747606689574338
Tax59.1775.0253.2532.83(162)99.0948.74
Net profit802814681565808453275
Net profit margin+26.3%+26.1%+23.3%+19.5%+28.2%+17.5%+11.5%
EPS (₹)19.2819.6815.8913.0019.2810.696.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital43.6543.6543.6544.1244.1244.4545.32
Reserves & surplus3,1122,8242,3392,2202,0421,7151,757
Shareholders' funds (net worth)3,1562,8672,3832,2642,0861,7591,802
Secured loans75.000.297.3910.7367.5825.2552.93
Unsecured loans16.6613.8114.859.8015621.28105
Total debt91.6614.1022.2420.5322446.53158
Total liabilities3,2842,9112,4372,3302,3541,8532,012
Assets
Gross block3,5563,5113,4753,4623,4402,9542,909
Net block7488409601,0881,2701,1001,422
Capital work in progress1.3712.475.191.702.636.328.05
Investments1,196995560392361264161
Inventories334259268292329269226
Sundry debtors19028528326019499.72182
Cash & bank balances31718291.1595.8055.6030857.30
Loans & advances273253213218227146252
Total current assets1,114978855866805823717
Total current liabilities442473410422471451423
Net working capital672505446444333372294
Total assets3,2842,9112,4372,3302,3541,8532,012
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash58.6427.7126.3213.123.243.57108
Net cash from operating activities794864740731596878546
Net cash from investing activities(257)(465)(192)(106)(188)(200)(251)
Net cash from financing activities(462)(368)(546)(612)(398)(679)(399)
Net change in cash75.4030.931.3913.209.88(0.33)(105)
Closing cash31718291.1595.8055.6030857.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-2.4%+6.9%+0.5%+1.4%+11.0%+8.1%-
EBITDA growth+0.3%+10.8%+8.8%-13.4%+6.4%+43.2%-
PBT growth-3.6%+25.1%+23.1%-12.0%+20.0%+70.0%-14.8%
Net income growth-1.5%+19.5%+20.5%-30.0%+78.4%+64.5%-
Revenue CAGR (3Y)+1.6%+2.9%+4.2%+6.7%+4.8%+3.1%+1.3%
EBITDA CAGR (3Y)+6.5%+1.5%+0.1%+9.7%+8.8%+6.4%-7.3%
Profitability & leverage
Net income margin+27.6%+27.5%+23.7%+19.7%+29.7%+18.4%+12.1%
Return on capital employed+29.1%+35.0%+31.4%+26.1%+32.9%+30.3%+17.1%
Return on net worth+28.0%+32.7%+29.8%+26.4%+44.3%+26.7%+15.0%
Debt / equity0.020.010.010.060.070.060.05
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.250.270.310.660.612.497.20
Efficiency & per share
Fixed asset turnover0.860.890.840.840.900.880.83
Inventory turnover10.2811.8610.439.369.5910.4310.88
Debtors turnover12.8611.0010.7712.8319.5518.3514.76
EPS (₹)19.2819.6815.8913.0019.2810.696.38
Dividend per share (₹)10.0010.008.008.008.008.004.00
Book value per share (₹)72.2965.6954.5951.3147.2839.5839.76

Top companies in Alternative Medicine Products

3 companies that operate in the same segment as LivAyur (Alternative Medicine Products) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Schwabe India
Homeopathic medicine manufacturing and online retail in India.
1898Noida, Uttar Pradesh, IndiaUSD 26.35 M1,192
Healthmug
Operates an online store specializing in ayurvedic and homeopathic medicines.
2016Delhi, Delhi, IndiaUSD 1.25 M16
Jiva Ayurveda
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness.
1992Faridabad, Haryana, IndiaUSD 10.08 M570
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Livayur

FMCG Giants Eye Stake in Farmley in ₹2,000 Crore Deal as Early Investors Seek Exit; Emami, ITC and Britannia Among Contenders
Exchange Update • 21 days ago
Emami: Company Board Passes Plan for ₹282 Crore Share Buyback at Maximum Price of ₹475 Per Share Through Open Market.
Exchange Update • 1 month ago
Emami : Goldman Sachs on Emami Maintains Buy with Target Price of ₹625 as the new business unit targets 20-30% CAGR while turning profitable, core business growth is expected to improve in FY27, and attractive valuations at 18x FY28E versus peers could drive a re-rating.
Exchange Update • 1 month ago
Emami Limited: Board Approves Share Buyback At ₹475 Each Through Open Market.
Exchange Update • 1 month ago
Emami: Company Will Review Share Buyback Proposal On September 17
Exchange Update • 1 month ago
Stock Market Live Updates 2 April 2025: Sensex, Nifty trade rangebound as markets await Trump’s Liberation Day proposals
Thehindubusinessline • 1 year ago
Stock Market Highlights 2 April 2025: Sensex, Nifty close higher as markets reassess impact of anticipated reciprocal tariffs
Thehindubusinessline • 1 year ago
Emami expects to revive Kesh King brand after BCG comes up with “robust strategy”
Thehindubusinessline • 1 year ago
Emami posts 7% rise in net profit to ₹278.98 cr in Q3FY25
Thehindubusinessline • 1 year ago
Q3 Results Live Today: CDSL shares end 10% lower, IDFC First Bank dips 8%, IOC, ACC down 3%; ICICI Bank, Yes Bank, AWL, Refex Industries’ stocks gain
Thehindubusinessline • 1 year ago
Premium access

Complete news archive for LivAyur

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about LivAyur

LivAyur was founded in 2019.

LivAyur is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

LivAyur has 3,328 employees.

The primary company behind LivAyur, Emami Limited, reported revenue of ₹3,865 Cr for FY 2026, down 1% year on year.

Livayur, under Emami Ltd, is a platform that shares ancient Ayurvedic knowledge with modern applications. It covers topics like healthy body management, nutritious food advice, natural healing remedies, and mental health support. Based in Kolkata, India, it provides e-books, live sessions, diagnostic tools, and products for conditions such as diabetes and immunity. The site serves individuals seeking holistic health solutions through educational content and direct purchases.

LivAyur offers Medha Vati, Panchakarma, and Ashwagandha.

Yes, LivAyur is publicly traded on NSE under the ticker symbol EMAMILTD.

LivAyur operates through Emami Limited.

The legal entities of LivAyur currently have 21 directors, including Chandra Kumar Dhanuka, Mamta Binani, Naresh Hiralal Bhansali and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available